Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 36

Results For "CEO"

1705 News Found

Merck to acquire life science company Mirus Bio for US$ 600 million
News | May 23, 2024

Merck to acquire life science company Mirus Bio for US$ 600 million

Acquisition will advance Merck’s integrated offering for viral vector manufacturing


Asymchem acquires former Pfizer small molecule API pilot plant in Sandwich, UK
News | May 23, 2024

Asymchem acquires former Pfizer small molecule API pilot plant in Sandwich, UK

Establishing Asymchem’s first manufacturing footprint in Europe


Indica Labs receives FDA clearance for HALO AP Dx digital pathology platform
Digitisation | May 23, 2024

Indica Labs receives FDA clearance for HALO AP Dx digital pathology platform

For use with Hamamatsu Images acquired with the NanoZoomer S360MD slide scanner


Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration
News | May 22, 2024

Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration

Sanofi will leverage this partnership to provide access to proprietary data to develop AI models


Biocon Biologics’ receives FDA approval for Biosimilar Aflibercept for Yesafili
Drug Approval | May 21, 2024

Biocon Biologics’ receives FDA approval for Biosimilar Aflibercept for Yesafili

The approval of YESAFILI marks Biocon Biologics’ expansion into the ophthalmology therapeutic area in the United States


IIHMR Start-ups inks MoU with BMCHRC & HCG Hospital
Startup | May 20, 2024

IIHMR Start-ups inks MoU with BMCHRC & HCG Hospital

The collaboration aims to bolster healthcare entrepreneurship


Biocon posts Q4 FY24 PAT at Rs. 135 Cr
News | May 17, 2024

Biocon posts Q4 FY24 PAT at Rs. 135 Cr

EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%


Cipla invests additional Rs. 26 crore in Achira
News | May 16, 2024

Cipla invests additional Rs. 26 crore in Achira

Achira is engaged in development and commercialization of PoC medical test kits in India


Lonza reports softer performance in Q1 2024
News | May 14, 2024

Lonza reports softer performance in Q1 2024

Outlook 2024 remains flat CER sales growth and CORE EBITDA margin of high 20s


Bayer Q1 2024 net income drops 8.2% to € 2 billion
News | May 14, 2024

Bayer Q1 2024 net income drops 8.2% to € 2 billion

EBITDA before special items falls 1.3 percent to € 4.41 billion